Skip to main content
. 2010 Oct;31(9):1588–1590. doi: 10.3174/ajnr.A2226

Fig 2.

Fig 2.

A, Natalizumab blocks the adhesion of leukocytes to endothelial cells by blocking the interaction of the α4-integrin subunit of α4β1 with VCAM-1 and of α4β7 with mucosal MAdCAM-1. B, This prevents autoreactive leukocytes from exiting blood vessels and entering target organs to cause inflammation.